$356.11 Million in Sales Expected for EXACT Sciences Co. (NASDAQ:EXAS) This Quarter

Wall Street analysts predict that EXACT Sciences Co. (NASDAQ:EXAS) will report sales of $356.11 million for the current quarter, according to Zacks. Seven analysts have made estimates for EXACT Sciences’ earnings. The lowest sales estimate is $322.90 million and the highest is $384.26 million. EXACT Sciences reported sales of $218.81 million during the same quarter last year, which indicates a positive year-over-year growth rate of 62.7%. The firm is expected to report its next quarterly earnings results on Tuesday, November 3rd.

According to Zacks, analysts expect that EXACT Sciences will report full-year sales of $1.39 billion for the current fiscal year, with estimates ranging from $1.32 billion to $1.44 billion. For the next year, analysts forecast that the firm will post sales of $1.91 billion, with estimates ranging from $1.75 billion to $2.07 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow EXACT Sciences.

EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Thursday, July 30th. The medical research company reported ($0.58) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.04. The firm had revenue of $268.87 million for the quarter, compared to analyst estimates of $229.62 million. EXACT Sciences had a negative return on equity of 13.32% and a negative net margin of 13.65%.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research upgraded EXACT Sciences from a “hold” rating to a “buy” rating and set a $97.00 price objective on the stock in a research report on Monday, July 13th. Oppenheimer restated a “buy” rating on shares of EXACT Sciences in a research report on Wednesday, July 8th. SVB Leerink lifted their price target on EXACT Sciences from $90.00 to $115.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Citigroup lifted their price target on EXACT Sciences from $110.00 to $120.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Finally, BidaskClub lowered EXACT Sciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 22nd. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $105.80.

Shares of EXAS stock opened at $76.01 on Thursday. The firm has a market cap of $11.41 billion, a P/E ratio of -71.71 and a beta of 1.70. EXACT Sciences has a fifty-two week low of $35.25 and a fifty-two week high of $113.10. The business’s 50 day moving average price is $82.24 and its 200-day moving average price is $78.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 6.40 and a current ratio of 6.77.

In other news, Director Katherine S. Zanotti sold 1,164 shares of the business’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $96.13, for a total value of $111,895.32. Following the completion of the transaction, the director now owns 41,907 shares in the company, valued at $4,028,519.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin T. Conroy sold 19,927 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $75.03, for a total value of $1,495,122.81. The disclosure for this sale can be found here. Insiders sold 65,538 shares of company stock valued at $5,721,343 in the last 90 days. Company insiders own 1.80% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Parallel Advisors LLC increased its position in EXACT Sciences by 13.5% during the second quarter. Parallel Advisors LLC now owns 901 shares of the medical research company’s stock valued at $78,000 after acquiring an additional 107 shares during the last quarter. Steward Partners Investment Advisory LLC increased its position in EXACT Sciences by 21.5% during the second quarter. Steward Partners Investment Advisory LLC now owns 706 shares of the medical research company’s stock valued at $61,000 after acquiring an additional 125 shares during the last quarter. CSat Investment Advisory L.P. increased its position in EXACT Sciences by 18.8% during the first quarter. CSat Investment Advisory L.P. now owns 826 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 131 shares during the last quarter. Synovus Financial Corp increased its position in EXACT Sciences by 16.6% during the second quarter. Synovus Financial Corp now owns 982 shares of the medical research company’s stock valued at $85,000 after acquiring an additional 140 shares during the last quarter. Finally, Curbstone Financial Management Corp increased its position in EXACT Sciences by 0.7% during the second quarter. Curbstone Financial Management Corp now owns 21,150 shares of the medical research company’s stock valued at $1,839,000 after acquiring an additional 150 shares during the last quarter. Hedge funds and other institutional investors own 87.15% of the company’s stock.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

See Also: Portfolio Manager

Get a free copy of the Zacks research report on EXACT Sciences (EXAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply